Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 40

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Diffuse large B-cell lymphoma+5

Not yet recruiting

Study of MDX2003 in Adults with Relapsed or Refractory B‑Cell Malignancies

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Acute myeloid leukaemia

Not yet recruiting

A Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Anaemia

Not yet recruiting

Effect of mitapivat versus placebo on transfusion burden in patients with sickle cell disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Sickle cell disease

Not yet recruiting

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Hodgkin's disease

Not yet recruiting

Phase II Study of Brentuximab Vedotin with Drug Combination in HIV‑Positive Patients with Advanced‑Stage Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:University Of Cologne

B-cell type acute leukaemia

Not yet recruiting

Phase II study of inotuzumab ozogamicin to prevent relapse in adult high‑risk acute lymphoblastic leukaemia patients after allogeneic stem cell transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inotuzumab Ozogamicin
  • Sponsor:Fundacion PETHEMA

Chronic lymphocytic leukaemia+2

Not yet recruiting

Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Grifols Therapeutics LLC

Mantle cell lymphoma+2

Not yet recruiting

Zoledronic acid prophylaxis for glucocorticoid‑induced osteoporosis in adult lymphoma patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Zoledronic Acid
  • Sponsor:Aalborg University Hospital

Diffuse large B-cell lymphoma

Not yet recruiting

Phase II study of fixed‑dose, accelerated ramp‑up epcoritamab plus lenalidomide in patients with relapsed/refractory large B‑cell lymphoma after CAR‑T therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Eosinophilic oesophagitis

Not yet recruiting

Dupilumab Maintenance Dose Optimization in Adults with Eosinophilic Esophagitis: A Randomized Controlled Non‑Inferiority Study

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Amsterdam UMC Stichting

Diffuse large B-cell lymphoma

Not yet recruiting

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.